| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma MA Postow, J Chesney, AC Pavlick, C Robert, K Grossmann, ... New England Journal of Medicine 372 (21), 2006-2017, 2015 | 3093 | 2015 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2185 | 2017 |
| Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 … FS Hodi, J Chesney, AC Pavlick, C Robert, KF Grossmann, DF McDermott, ... The Lancet Oncology 17 (11), 1558-1568, 2016 | 990 | 2016 |
| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 883 | 2021 |
| Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ... The Lancet Oncology 18 (7), 863-873, 2017 | 704 | 2017 |
| A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma C Bertolotto, F Lesueur, S Giuliano, T Strub, M De Lichy, K Bille, P Dessen, ... Nature 480 (7375), 94-98, 2011 | 595 | 2011 |
| Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients M Delaunay, J Cadranel, A Lusque, N Meyer, V Gounant, D Moro-Sibilot, ... European Respiratory Journal 50 (2), 2017 | 381 | 2017 |
| TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma F Bertrand, A Montfort, E Marcheteau, C Imbert, J Gilhodes, T Filleron, ... Nature communications 8 (1), 2256, 2017 | 333 | 2017 |
| Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ... Journal of Clinical Oncology 37 (11), 867, 2019 | 312 | 2019 |
| Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial N Basset-Séguin, A Hauschild, R Kunstfeld, J Grob, B Dréno, L Mortier, ... European journal of cancer 86, 334-348, 2017 | 300 | 2017 |
| Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial N Basset-Seguin, A Hauschild, JJ Grob, R Kunstfeld, B Dréno, L Mortier, ... The Lancet Oncology 16 (6), 729-736, 2015 | 296 | 2015 |
| The TNF paradox in cancer progression and immunotherapy A Montfort, C Colacios, T Levade, N Andrieu-Abadie, N Meyer, B Ségui Frontiers in immunology 10, 457367, 2019 | 272 | 2019 |
| Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies V Sibaud, N Meyer, L Lamant, E Vigarios, J Mazieres, JP Delord Current opinion in oncology 28 (4), 254-263, 2016 | 272 | 2016 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 248 | 2021 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis L Legendre, T Barnetche, J Mazereeuw-Hautier, N Meyer, D Murrell, ... Journal of the American Academy of Dermatology 72 (6), 992-1002, 2015 | 206 | 2015 |
| High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes L Martinet, S Le Guellec, T Filleron, L Lamant, N Meyer, P Rochaix, ... Oncoimmunology 1 (6), 829-839, 2012 | 200 | 2012 |
| Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629) JJ Grob, R Gonzalez, N Basset-Seguin, O Vornicova, J Schachter, A Joshi, ... Journal of Clinical Oncology 38 (25), 2916, 2020 | 194 | 2020 |
| Geoepidemiologic considerations of auto-immune pemphigus N Meyer, L Misery Autoimmunity Reviews 9 (5), A379-A382, 2010 | 133 | 2010 |
| Psoriasis: an epidemiological evaluation of disease burden in 590 patients N Meyer, C Paul, D Feneron, I Bardoulat, C Thiriet, C Camara, ... Journal of the European Academy of Dermatology and Venereology 24 (9), 1075-1082, 2010 | 129 | 2010 |
Carle PaulUniversité Toulouse 3 Paul SabatierVerified email at chu-toulouse.fr
